World Neuroendocrine Cancer Day: New Targeted Therapies for NETs

November 10, 2021

Dr. Arturo Loaiza-Bonilla, Cancer Treatment Centers of America® (CTCA) Enterprise Research Program Director, discussed recent trials and advances in neuroendocrine cancer research in an interview with Targeted Oncology for World Neuroendocrine Cancer Day.

“There is an increased interest in this disease type that historically was mostly orphaned, or even considered non-malignant, which of course is not the case. While we are still in the process of understanding the results of ongoing clinical trials, the encouraging news is the proliferation of clinical trials related to the neuroendocrine space.”

Read more here

About Cancer Treatment Centers of America
Cancer Treatment Centers of America® (CTCA) is a national oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. Visit cancercenter.com for more information.